Bellevue Group AG grew its holdings in shares of Illumina, Inc. (NASDAQ:ILMN) by 10.8% in the 2nd quarter, Holdings Channel reports. The firm owned 140,971 shares of the life sciences company’s stock after purchasing an additional 13,698 shares during the quarter. Illumina makes up approximately 3.4% of Bellevue Group AG’s investment portfolio, making the stock its 5th largest position. Bellevue Group AG’s holdings in Illumina were worth $39,372,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Sumitomo Mitsui Asset Management Company LTD increased its holdings in Illumina by 1.8% in the 2nd quarter. Sumitomo Mitsui Asset Management Company LTD now owns 10,241 shares of the life sciences company’s stock worth $2,860,000 after acquiring an additional 179 shares in the last quarter. Private Asset Management Inc. increased its holdings in Illumina by 1.6% in the 2nd quarter. Private Asset Management Inc. now owns 11,243 shares of the life sciences company’s stock worth $3,140,000 after acquiring an additional 180 shares in the last quarter. Dempze Nancy E increased its holdings in Illumina by 3.7% in the 2nd quarter. Dempze Nancy E now owns 5,432 shares of the life sciences company’s stock worth $1,517,000 after acquiring an additional 194 shares in the last quarter. World Asset Management Inc increased its holdings in Illumina by 2.1% in the 2nd quarter. World Asset Management Inc now owns 9,908 shares of the life sciences company’s stock worth $2,767,000 after acquiring an additional 208 shares in the last quarter. Finally, Fox Run Management L.L.C. increased its holdings in Illumina by 21.6% in the 2nd quarter. Fox Run Management L.L.C. now owns 1,220 shares of the life sciences company’s stock worth $341,000 after acquiring an additional 217 shares in the last quarter. 90.80% of the stock is owned by hedge funds and other institutional investors.

ILMN stock opened at $330.17 on Wednesday. Illumina, Inc. has a 1-year low of $189.15 and a 1-year high of $341.08. The company has a quick ratio of 2.44, a current ratio of 2.74 and a debt-to-equity ratio of 0.22. The company has a market capitalization of $48.55 billion, a price-to-earnings ratio of 82.54, a price-to-earnings-growth ratio of 2.76 and a beta of 0.97.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings results on Monday, July 30th. The life sciences company reported $1.43 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.11 by $0.32. Illumina had a return on equity of 26.64% and a net margin of 20.88%. The business had revenue of $830.00 million during the quarter, compared to the consensus estimate of $786.88 million. During the same period in the prior year, the company posted $0.82 EPS. The firm’s revenue for the quarter was up 25.4% compared to the same quarter last year. sell-side analysts expect that Illumina, Inc. will post 5.41 EPS for the current fiscal year.

ILMN has been the subject of several analyst reports. Morgan Stanley increased their target price on shares of Illumina from $195.00 to $210.00 and gave the stock an “underweight” rating in a report on Friday, July 13th. BidaskClub raised shares of Illumina from a “buy” rating to a “strong-buy” rating in a report on Thursday, April 19th. Canaccord Genuity increased their target price on shares of Illumina from $270.00 to $290.00 and gave the stock a “top pick” rating in a report on Tuesday, May 29th. Barclays raised shares of Illumina from an “equal weight” rating to an “overweight” rating and set a $235.00 target price for the company in a report on Monday, May 7th. Finally, ValuEngine lowered shares of Illumina from a “buy” rating to a “hold” rating in a report on Thursday, April 26th. Five investment analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $303.53.

In other news, SVP Mostafa Ronaghi sold 10,000 shares of the stock in a transaction that occurred on Friday, August 10th. The stock was sold at an average price of $331.39, for a total transaction of $3,313,900.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Francis A. Desouza sold 2,100 shares of the stock in a transaction that occurred on Monday, July 2nd. The shares were sold at an average price of $276.14, for a total value of $579,894.00. Following the transaction, the chief executive officer now owns 83,282 shares of the company’s stock, valued at $22,997,491.48. The disclosure for this sale can be found here. Insiders sold a total of 43,381 shares of company stock valued at $12,975,231 over the last 90 days. 0.54% of the stock is currently owned by corporate insiders.

Illumina Profile

Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing by synthesis technology that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as allow the detection of known genetic markers on a single array.

Featured Article: Relative Strength Index

Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN).

Institutional Ownership by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.